QMS Medical Allied Services profit and loss

Latest FY26

Revenue: ₹173cr+10.8% on FY25
EBITDA: ₹25.9cr+1.9% on FY25
Net profit: ₹11.9cr−13.0% on FY25
EPS: ₹5.40−20.2% on FY25

₹ crore except per share

Tap a line for its trend	Last 12Mto Jun 2026	FY26Mar 2026	FY25Mar 2025

Expenses
	267	173	156
	1.8	1.1	1.7
	269	174	158
	155	100	81.3
	−16.9	−7.5	0.3
	29.4	15.2	9.6
	10.0	6.6	4.6
	6.4	3.9	3.8
	59.0	39.2	39.4
	243	157	139
	40.9	25.9	25.4
	34.5	21.9	21.6
Profit
	26.3	16.4	18.7
	26.3	16.4	18.7
	7.1	4.7	5.5
	0.2	−0.2	−0.5
	7.2	4.5	5.0
	19.0	11.9	13.7
Per share
	₹8.72	₹5.40	₹6.77
	₹8.72	₹5.40	₹6.77
Profit build-up — alternate / pre-Ind-AS tags
	—	16.4	18.7
	—	8.8	3.5
	—	11.9	13.7
Continuing & discontinued operations
	—	11.9	13.7
Derived — gross profit (revenue − materials − purchases − Δ inventories)
	129	80.2	74.4
	48.4%	46.4%	47.7%
Adjusted (ex-exceptional items) — derived
	26.3	16.4	18.7
	19.0	11.9	13.7
	₹8.72	₹5.40	₹6.77

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

QMSMEDI₹177.18

QMS Medical Allied Services Limited

· Pharma & Health

Annual Quarterly₹ CroreMcap ₹343 Cr

View

In ₹ Crore except Per Share 12 Months Ending	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/06/2026
Revenue from Operations	156.0	172.9	267.0
Other Income	1.7	1.1	1.8
Total Income	157.7	173.9	268.8
Expenses
+ Purchases of Stock-in-Trade	81.3	100.1	154.6
+ Changes in Inventories	0.3	-7.5	-16.9
+ Employee Benefit Expense	9.6	15.2	29.4
+ Finance Costs	4.6	6.6	10.0
+ Depreciation & Amortisation	3.8	3.9	6.4
+ Other Expenses	39.4	39.2	59.0
Total Expenses	139.1	157.5	242.5
EBITDA	25.4	25.9	40.9
EBIT	21.6	21.9	34.5
Profit
PBT before Exceptional Items	18.7	16.4	26.3
Pretax Income	18.7	16.4	26.3
+ Current Tax	5.5	4.7	7.1
+ Deferred Tax	-0.5	-0.2	0.2
Tax Expense	5.0	4.5	7.2
Net Income	13.7	11.9	19.0
Per Share
Basic EPS	6.77	5.40	8.72
Diluted EPS	6.77	5.40	8.72
Profit Build-up — Alternate / Pre-Ind-AS Tags
PBT before Exceptional & Extraordinary Items	18.7	16.4	—
+ Adjustments to Profit / (Loss)	3.5	8.8	—
Profit for the Period before Minority Interest	13.7	11.9	—
Continuing & Discontinued Operations
Profit from Continuing Operations	13.7	11.9	—
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit	74.4	80.2	129.3
Gross Margin %	47.70	46.42	48.44
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)	18.7	16.4	26.3
Net Income Adj (tax-effected)	13.7	11.9	19.0
EPS Adj	6.77	5.40	8.72
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value	10.00	10.00	10.00
Filed Debt Equity	—	0.12	0.12
Filed Dscr	—	1.51	1.81
Filed Iscr	—	4.45	5.10
Paid Up Equity Capital	17.9	19.3	19.3

As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.